{{noteTA
|1 =zh:勃林格殷格翰; zh-hk:寶靈家殷格翰; zh-tw:百靈佳殷格翰;
}}

{{Drugbox
| Watchedfields = changed
| verifiedrevid = 443756837
| IUPAC_name = (''RR'',''SS'')-5-(1-hydroxy-2-<nowiki/>{[2-(4-hydroxyphenyl)-1-methylethyl]amino}ethyl)benzene-1,3-diol
| image = File:(RR)- and (SS)- fenoterol.svg
| width = 265
| image2 = Fenoterol ball-and-stick model.png

<!--Clinical data-->
| tradename = 
| Drugs.com = {{drugs.com|CONS|Fenoterol}}
| pregnancy_AU =
| pregnancy_US = B
| pregnancy_category =
| legal_AU = s3
| legal_CA = Rx-Only
| legal_UK = POM        
| legal_US = Rx-only  
| routes_of_administration = Inhalation ({{tsl|en|Metered-dose inhaler||MDI}})

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life = 6.5小時左右 <ref name="Drugs.com 1996">{{cite web | title=Fenoterol Hydrobromide Drug Information, Professional | website=Drugs.com | date=1996-01-01 | url=https://www.drugs.com/mmx/fenoterol-hydrobromide.html | access-date=2018-06-11}}</ref><ref name="DrugInfoSys.com 2016">{{cite web | title=Fenoterol - Drug Monograph | website=DrugInfoSys.com | date=2016-10-27 | url=http://www.druginfosys.com/drug.aspx?drugcode=303&type=1 | access-date=2018-06-11}}</ref><ref name="RxMed.com">{{cite web | title=Berotec Inhalation Solution (Fenoterol HBr) | website=RxMed.com | url=https://www.rxmed.com/b.main/b2.pharmaceutical/b2.1.monographs/cps-_monographs/CPS-_(General_Monographs-_B)/BEROTEC_INHALATION_SOLUTION.html | access-date=2018-06-11}}</ref><ref name="Svedmyr pp. 109–126">{{cite journal | last=Svedmyr | first=Nils | title=Fenoterol: A Beta2-adrenergic Agonist for Use in Asthma; Pharmacology, Pharmacokinetics, Clinical Efficacy and Adverse Effects | journal=Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy | publisher=Wiley | volume=5 | issue=3 | date=1985-05-06 | issn=0277-0008 | doi=10.1002/j.1875-9114.1985.tb03409.x | pages=109–126}}</ref>
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 13392-18-2
| ATC_prefix = R03
| ATC_suffix = AC04
| ATC_supplemental =  {{ATC|G02|CA03}}
| PubChem = 3343
| IUPHAR_ligand = 557
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01288
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 3226
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 22M9P70OQ9
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D04157
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 149226
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 32800

<!--Chemical data-->
| C=17 | H=21 | N=1 | O=4
| molecular_weight = 303.35 g/mol
| smiles = Oc1cc(cc(O)c1)C(O)CNC(C)Cc2ccc(O)cc2
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C17H21NO4/c1-11(6-12-2-4-14(19)5-3-12)18-10-17(22)13-7-15(20)9-16(21)8-13/h2-5,7-9,11,17-22H,6,10H2,1H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = LSLYOANBFKQKPT-UHFFFAOYSA-N
}}
{{confused|福莫特罗}}
{{medical}}

'''非诺特罗'''（Fenoterol） 是一種用來擴張[[呼吸道|呼吸道]]的[[Β2肾上腺素受体激动药|β<sub>2</sub>肾上腺素受体激动药]]。非诺特罗 屬於[[拟交感神经药|拟交感神经药]] β<sub>2</sub> 刺激劑和[[氣喘|氣喘]]藥。

非诺特罗 由[[勃林格殷格翰|勃林格殷格翰]]製造和銷售，商品名稱為：'''Berotec N''' （'''備勞喘'''）。製造商有時也會把非诺特罗與[[異丙托溴銨|ipratropium]]混和後銷售，商品名稱同樣為 Berotec N。
==醫學用途==
非诺特罗 是短效的 β<sub>2</sub>刺激劑。當非诺特罗使用超過建議的醫療用劑量（每日最多只能吸入八劑、每劑量需間隔至少五分鐘，若[[氣喘|氣喘]]狀況沒好轉，則再吸入第二劑<ref>{{cite web| url=http://www.mims.com/malaysia/drug/info/berotec%20n/?type=full | date=2018-2-28 | title=Berotec N/Concise Prescribing Info/Full Prescribing info| quote=Dosage / Direction for Use：<br/>'''Acute Asthma Episodes''': 1 puff is sufficient for prompt symptom relief in most cases, if breathing has not noticeably improved after 5 minutes, a second dose may be taken, up to a maximum of 8 puffs per day. If an attack has not been relieved by 2 puffs, further puffs may be required. In this situation, patients should consult the doctor or the nearest hospital immediately. (See Precautions).<br/>'''Prophylaxis of Exercise Induced Asthma''': 1-2 puffs prior to exercise, up to a maximum of 8 puffs per day.<br/>'''Bronchial Asthma and Other Conditions with Reversible Airways Narrowing''': If repeated dosing is required, 1-2 puffs for each administration, up to a maximum of 8 puffs per day.}}</ref>）時，也會成為{{tsl|en|Beta-1 adrenergic receptor||β<sub>1</sub> 受體}}刺激劑。

使用者可以於[[體能鍛鍊|運動]]前吸入一劑，預防稍後因運動所誘發的氣喘（氣管痙攣）。<ref name="UpToDate">{{cite web | title=Management of acute exacerbations of asthma in adults | website=UpToDate | url=https://www.uptodate.com/contents/management-of-acute-exacerbations-of-asthma-in-adults?search=fenoterol&source=search_result&selectedTitle=4~6&usage_type=default&display_rank=4 | access-date=2018-06-25}}</ref>
===副作用===
已知曾有患者在急性氣喘發作時吸入了高達80劑的非诺特罗，最終因而死亡。當患者發現非诺特罗已經無法緩解[[氣喘|氣喘]]時，應當停止吸入非诺特罗，並盡快就醫。<ref name="pmid7613161">{{cite journal |vauthors=Beasley R, Pearce N, Crane J, Burgess C |title=Withdrawal of 非诺特罗 and the end of the New Zealand asthma mortality epidemic |journal=International Archives of Allergy and Immunology |volume=107 |issue=1-3 |pages=325–7 |year=1995 |pmid=7613161 |doi= 10.1159/000237016|url=}}</ref><ref name="pmid1346340">{{cite journal |vauthors=Spitzer WO, Suissa S, Ernst P |title=The use of beta-agonists and the risk of death and near death from asthma |journal=The New England Journal of Medicine |volume=326 |issue=8 |pages=501–6 |date=February 1992 |pmid=1346340 |doi= 10.1056/NEJM199202203260801|url=|display-authors=etal}}</ref>

[[File:Berotec.jpg|thumb]]
[[File:Berotec_in_Chinese.jpg|thumb]]

==參見==
*{{tsl|en|Exercise-induced bronchoconstriction|運動引起的氣管收縮|運動引起的氣喘}}

==文獻來源==
{{reflist}}

{{Drugs for obstructive airway diseases}}
<!--{{Other gynecologicals}}-->
{{Adrenergic agonists}}
{{Other gynecologicals}}


[[Category:Beta2-adrenergic_agonists|Category:Beta2-adrenergic agonists]]
[[Category:间苯二酚|Category:间苯二酚]]
[[Category:苯丙胺类|Category:苯丙胺类]]